Cancer-related fatigue

Last updated

Cancer-related fatigue is a symptom of fatigue that is experienced by nearly all cancer patients. [1]

Contents

Among patients receiving cancer treatment other than surgery, it is essentially universal. Fatigue is a normal and expected side effect of most forms of chemotherapy, radiation therapy, and biotherapy. [2] On average, cancer-related fatigue is "more severe, more distressing, and less likely to be relieved by rest" than fatigue experienced by healthy people. [2] It can range from mild to severe, and may be either temporary or a long-term effect.

Fatigue may be a symptom of the cancer, or it may be the result of treatments for the cancer.

Pathophysiology

The pathophysiology of cancer-related fatigue is poorly understood. It may be caused by the cancer or the effects it has on the body, by the body's response to the cancer, or by the cancer treatments.

Fatigue is a common symptom of cancer. [3]

Some fatigue is caused by cancer treatments. This may show a characteristic pattern. For example, people on many chemotherapy regimens often feel more fatigue in the week after treatments, and less fatigue as they recover from that round of medications. People receiving radiation therapy, by contrast, often find their fatigue steadily increases until the end of treatment. [3]

Proposed mechanisms by which cancer can cause fatigue include an increase in pro-inflammatory cytokines, dysregulation of the hypothalamic-pituitary-adrenal axis, disruption of circadian rhythms, muscle loss and cancer wasting, and genetic problems. [2] Additionally, some forms of cancer may cause fatigue through more direct mechanisms, such as a leukemia that causes anemia by preventing the bone marrow from producing blood cells efficiently. A relationship between Interleukin 6 and fatigue has been observed in studies, albeit inconsistently. Increased markers of sympathetic nervous system activity are also associated with cancer related fatigue. [4]

Screening

The National Comprehensive Cancer Network recommends that every cancer patient be systematically screened for fatigue at the first visit with an oncologist, throughout treatment, and afterwards. [2] Screening typically involves a simple question, like "On a scale of one to ten, how tired have you felt during the last week?"

More detailed information may be collected in a symptom journal.

Diagnosis

Some causes of cancer-related fatigue are treatable, and evaluation is directed towards identifying these treatable causes. Treatable causes of cancer-related fatigue include: anemia, pain, emotional distress, sleep disturbances, nutritional disturbances, decreased physical fitness and activity, side effects from medications (e.g., sedatives), abuse of alcohol or other substances. [2] Additionally, other medical conditions, such as infections, heart disease, or endocrine dysfunction (e.g., hot flashes), can cause fatigue, and may also need treatment.

Definition

The National Comprehensive Cancer Network defines cancer-related fatigue as "a distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning". [2]

Cancer-related fatigue is a chronic fatigue (persistent fatigue not relieved by rest), but it is not related to chronic fatigue syndrome. [3] Cancer-related fatigue occurs in a significant proportion of cancer survivors, both during and after cancer treatment. [5] A review of current evidence indicates that exercise is the most effective way of ameliorating cancer-related fatigue. [5]

Prostate cancer

Cancer related fatigue is common in patients undergoing treatment for prostate cancer. [6] A systematic review of the prevalence of cancer-related fatigue in men with prostate cancer was performed. [7] The analysis indicated that fatigue is a common symptom, occurring in about 40% of men with prostate cancer especially among those using hormone therapy. [7]

Management

Treatment depends on the patient's overall situation. A patient who is in active treatment may have different priorities than a person who has completed treatment, or who is at the end of life.

Some management strategies may help all patients and could be supported by the work of an Occupational Therapist. These include scheduling high-priority tasks during the patient's best time of day, using labor-saving devices, delegating tasks to caregivers, and avoiding unimportant activities, so that the patient will have more energy available for other activities. [8]

Patients who are not at the end of life may benefit from physical exercise or physical therapy. Engaging in physical activity may reduce fatigue. [2] [9] [10] [11] Forms of exercise that have been proven to be most effective are more aerobic exercise such as walking, running, cycling, and swimming. These forms of activity can be done at various levels of intensity and have been proven as an effective way of improving QOL for cancer patients. [12]

While antidepressants are ineffective at reducing fatigue in non-depressed cancer patients, psychostimulants such as methylphenidate and amphetamines may reduce fatigue in some patients. [2] [13] [14] [15] [16] The findings of a study conducted by researchers from reputable universities in the UK indicate that methylphenidate may be effective in the management of CRF (Cancer Related Fatigue). If methylphenidate were to be used in patients with CRF, it would be prudent to restrict its use to patients with advanced disease or for short-term use in patients on active treatment. The clear advantage of methylphenidate in cancer is its rapid onset of action within 24–48 hours, and so the drug can be discontinued if ineffective. [17]

At the end of life, fatigue is usually associated with other symptoms, especially anemia, side effects from many medications and previous treatments, and poor nutritional status. [2] Pain, difficulty breathing, and fatigue form a common symptom cluster. Fatigue often increases as patients with advanced cancer approach death. As a result, people who are dying often sleep much more than a healthy person. [18] [19]

Addressing specific causes

If the fatigue is caused or exacerbated by a specific medical condition, such as anemia, then treatment of that medical condition should reduce the fatigue.

Prognosis

Fatigue caused by the cancer or its treatment often resolves if treatment is successful. However, some patients experience long-term or chronic fatigue. When strict definitions are used, about 20% of long-term, disease-free cancer survivors report fatigue. [2] Under looser definitions, up to half of cancer survivors report fatigue. [2] However, these studies are largely limited to patients with breast cancer, or peripheral stem cell transplant or bone marrow transplant patients, and the incidence may be different for survivors of other cancers.

Experiencing fatigue before treatment, being depressed or anxious, getting too little exercise, and having other medical conditions are all associated with higher levels of fatigue in post-treatment cancer survivors. [2] Receiving multiple types of treatments, such as chemotherapy and radiation, is associated with more fatigue. [3] Older adults have a higher risk of long-term fatigue. [3]

Cancer-related fatigue has consistently been found to be one of the most prevalent and distressing symptoms in childhood cancer survivors. [23] The International Late Effects of Childhood Cancer Guidelines Harmonization Group (IGHG) has published recommendations regarding the surveillance of fatigue in survivors of childhood cancer. [24] These recommendations include regular screenings of fatigue in survivors of childhood cancer. Survivors of pediatric brain tumors report more fatigue after end of treatment than survivors of acute lymphoblastic leukemia, but both groups experience more fatigue than healthy children and adolescents. [25] While considered a long-term effect of the treatment, children and adolescents experience fatigue already during the treatment for acute lymphoblastic leukemia and this side-effect of treatment remains in some patients after the treatment has ended. [26] Fatigue after treatment for pediatric brain tumors does not automatically resolve itself, but requires surveillance and interventions. [27]

Related Research Articles

<span class="mw-page-title-main">Insomnia</span> Disorder causing trouble with sleeping

Insomnia, also known as sleeplessness, is a sleep disorder where people have trouble sleeping. They may have difficulty falling asleep, or staying asleep for as long as desired. Insomnia is typically followed by daytime sleepiness, low energy, irritability, and a depressed mood. It may result in an increased risk of accidents of all kinds as well as problems focusing and learning. Insomnia can be short term, lasting for days or weeks, or long term, lasting more than a month. The concept of the word insomnia has two distinct possibilities: insomnia disorder (ID) or insomnia symptoms, and many abstracts of randomized controlled trials and systematic reviews often underreport on which of these two possibilities the word refers to.

<span class="mw-page-title-main">Attention deficit hyperactivity disorder</span> Neurodevelopmental disorder

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by executive dysfunction occasioning symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and developmentally-inappropriate.

<span class="mw-page-title-main">Shortness of breath</span> Feeling of difficulty breathing

Shortness of breath (SOB), known as dyspnea or dyspnoea, is an uncomfortable feeling of not being able to breathe well enough. The American Thoracic Society defines it as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity", and recommends evaluating dyspnea by assessing the intensity of its distinct sensations, the degree of distress and discomfort involved, and its burden or impact on the patient's activities of daily living. Distinct sensations include effort/work to breathe, chest tightness or pain, and "air hunger". The tripod position is often assumed to be a sign.

<span class="mw-page-title-main">Methylphenidate</span> Central nervous system stimulant

Methylphenidate, sold under the brand names Ritalin and Concerta among others, is a FDA-approved central nervous system (CNS) stimulant to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It may be taken by mouth or applied to the skin, and different formulations have varying durations of effect. For ADHD, the effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamines, alleviating the executive functioning deficits of sustained attention, inhibition, working memory, reaction time and emotional self-regulation.

<span class="mw-page-title-main">Fatigue</span> Range of afflictions, usually associated with physical or mental weakness

Fatigue is a state of tiredness, exhaustion or loss of energy.

<span class="mw-page-title-main">Fibromyalgia</span> Chronic pain of unknown cause

Fibromyalgia is a medical syndrome that causes chronic widespread pain, accompanied by fatigue, awakening unrefreshed, and cognitive symptoms. Other symptoms can include headaches, lower abdominal pain or cramps, and depression. People with fibromyalgia can also experience insomnia and general hypersensitivity. The cause of fibromyalgia is unknown, but is believed to involve a combination of genetic and environmental factors. Environmental factors may include psychological stress, trauma, and some infections. Since the pain appears to result from processes in the central nervous system, the condition is referred to as a "central sensitization syndrome". Although a protocol using an algometer (algesiometer) for determining central sensitization has been proposed as an objective diagnostic test, fibromyalgia continues to be primarily diagnosed by exclusion despite the high possibility of misdiagnosis.

<span class="mw-page-title-main">Post-polio syndrome</span> Human disease

Post-polio syndrome is a group of latent symptoms of poliomyelitis (polio), occurring in more than 80% of polio infections. The symptoms are caused by the damaging effects of the viral infection on the nervous system and typically occur 15 to 30 years after an initial acute paralytic attack. Symptoms include decreasing muscular function or acute weakness with pain and fatigue. The same may also occur years after a nonparalytic polio infection.

<span class="mw-page-title-main">Dextroamphetamine</span> CNS stimulant and isomer of amphetamine

Dextroamphetamine is a potent central nervous system (CNS) stimulant and enantiomer of amphetamine that is primarily prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It has also been used illicitly to enhance cognitive and athletic performance, as well as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant.

<span class="mw-page-title-main">Chest pain</span> Discomfort or pain in the chest as a medical symptom

Chest pain is pain or discomfort in the chest, typically the front of the chest. It may be described as sharp, dull, pressure, heaviness or squeezing. Associated symptoms may include pain in the shoulder, arm, upper abdomen, or jaw, along with nausea, sweating, or shortness of breath. It can be divided into heart-related and non-heart-related pain. Pain due to insufficient blood flow to the heart is also called angina pectoris. Those with diabetes or the elderly may have less clear symptoms.

<span class="mw-page-title-main">Adderall</span> Drug mixture used mainly to treat ADHD and narcolepsy

Adderall and Mydayis are trade names for a combination drug containing four salts of amphetamine. The mixture is composed of equal parts racemic amphetamine and dextroamphetamine, which produces a (3:1) ratio between dextroamphetamine and levoamphetamine, the two enantiomers of amphetamine. Both enantiomers are stimulants, but differ enough to give Adderall an effects profile distinct from those of racemic amphetamine or dextroamphetamine, which are marketed as Evekeo and Dexedrine/Zenzedi, respectively. Adderall is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used illicitly as an athletic performance enhancer, cognitive enhancer, appetite suppressant, and recreationally as a euphoriant. It is a central nervous system (CNS) stimulant of the phenethylamine class.

<span class="mw-page-title-main">Sleep hygiene</span> Set of practices around healthy sleeping

Sleep hygiene is a behavioral and environmental practice developed in the late 1970s as a method to help people with mild to moderate insomnia. Clinicians assess the sleep hygiene of people with insomnia and other conditions, such as depression, and offer recommendations based on the assessment. Sleep hygiene recommendations include establishing a regular sleep schedule, using naps with care, not exercising physically too close to bedtime, limiting worry, limiting exposure to light in the hours before sleep, getting out of bed if sleep does not come, not using bed for anything but sleep and sex, avoiding alcohol in the hours before bedtime, and having a peaceful, comfortable and dark sleep environment.

<span class="mw-page-title-main">Cancer survivor</span> Person with cancer who is still alive

A cancer survivor is a person with cancer of any type who is still living. Whether a person becomes a survivor at the time of diagnosis or after completing treatment, whether people who are actively dying are considered survivors, and whether healthy friends and family members of the cancer patient are also considered survivors, varies from group to group. Some people who have been diagnosed with cancer reject the term survivor or disagree with some definitions of it.

Myofascial pain syndrome (MPS), also known as chronic myofascial pain (CMP), is a syndrome characterized by chronic pain in multiple myofascial trigger points ("knots") and fascial constrictions. It can appear in any body part. Symptoms of a myofascial trigger point include: focal point tenderness, reproduction of pain upon trigger point palpation, hardening of the muscle upon trigger point palpation, pseudo-weakness of the involved muscle, referred pain, and limited range of motion following approximately 5 seconds of sustained trigger point pressure.

Progressive muscle relaxation (PMR) is a method of deep muscle relaxation that does not involve any medications, meaning it is a non-pharmacological intervention. The idea behind progressive muscle relaxation is that there is a relationship between a person's mind and body. The body responds to its environment by creating certain mind or body states such as anxiety, stress, and fear. When the body is in these states, the muscles tense up. Progressive muscle relaxation aims to reverse these body states back to more neutral, relaxed states.

Psycho-oncology is an interdisciplinary field at the intersection of physical, psychological, social, and behavioral aspects of the cancer experience for both patients and caregivers. Also known as psychiatric oncology or psychosocial oncology, researchers and practitioners in the field are concerned with aspects of individuals' experience with cancer beyond medical treatment, and across the cancer trajectory, including at diagnosis, during treatment, transitioning to and throughout survivorship, and approaching the end-of-life. Founded by Jimmie Holland in 1977 via the incorporation of a psychiatric service within the Memorial Sloan Kettering Cancer Center in New York, the field has expanded drastically since and is now universally recognized as an integral component of quality cancer care. Cancer centers in major academic medical centers across the country now uniformly incorporate a psycho-oncology service into their clinical care, and provide infrastructure to support research efforts to advance knowledge in the field.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

Post-chemotherapy cognitive impairment (PCCI) describes the cognitive impairment that can result from chemotherapy treatment. While there is no concrete statistic for the number of patients that experience some level of post-chemotherapy cognitive impairment, the estimated percentage is between 13 and 70 percent of patients. The phenomenon first came to light because of the large number of breast cancer survivors who complained of changes in memory, fluency, and other cognitive abilities that impeded their ability to function as they had pre-chemotherapy.

Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD. Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training, neurofeedback, neurostimulation, physical exercise, nutrition and supplements, integrative medicine, parent support, and school interventions. Based on two 2024 systematic reviews of the literature, FDA-approved medications and to a lesser extent psychosocial interventions have been shown to improve core ADHD symptoms compared to control groups.

Management of ME/CFS focuses on symptoms management, as no treatments that address the root cause of the illness are available. Pacing, or regulating one's activities to avoid triggering worse symptoms, is the most common management strategy for post-exertional malaise. Clinical management varies widely, with many patients receiving combinations of therapies. The prognosis of ME/CFS is poor, with recovery considered “rare”.

<span class="mw-page-title-main">Myalgic encephalomyelitis/chronic fatigue syndrome</span> Chronic medical condition

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling chronic illness. People with ME/CFS experience profound fatigue that does not go away with rest, as well as sleep issues and problems with memory or concentration. The hallmark symptom is post-exertional malaise, a worsening of the illness which can start immediately or hours to days after even minor physical or mental activity. This "crash" can last from hours or days to several months. Further common symptoms include dizziness or faintness when upright and pain.

References

  1. ↑ Hofman, Maarten; Ryan, Julie L.; Figueroa-Moseley, Colmar D.; Jean-Pierre, Pascal; Morrow, Gary R. (2007-05-01). "Cancer-Related Fatigue: The Scale of the Problem". The Oncologist. 12 (S1): 4–10. doi:10.1634/theoncologist.12-s1-4. ISSN   1083-7159. PMID   17573451.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 "NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue" (PDF) (Version 1.2010 ed.). National Comprehensive Cancer Network. 22 January 2010.
  3. 1 2 3 4 5 6 7 8 "Fatigue". National Cancer Institute. 1980-01-01. Retrieved 6 October 2010.
  4. ↑ Saligan LN, Olson K, Filler K, Larkin D, Cramp F, Yennurajalingam S, et al. (August 2015). "The biology of cancer-related fatigue: a review of the literature". Supportive Care in Cancer. 23 (8): 2461–2478. doi:10.1007/s00520-015-2763-0. PMC   4484308 . PMID   25975676.
  5. 1 2 Thong MS, van Noorden CJ, Steindorf K, Arndt V (February 2020). "Cancer-Related Fatigue: Causes and Current Treatment Options". Curr Treat Options Oncol. 21 (2): 17. doi:10.1007/s11864-020-0707-5. PMC   8660748 . PMID   32025928.
  6. ↑ Randall J, Haque W, Butler EB, Teh BS (March 2019). "Cancer related fatigue in prostate cancer". Translational Andrology and Urology. 8 (Suppl 1): S106 –S108. doi: 10.21037/tau.2018.12.06 . PMC   6511691 . PMID   31143682.
  7. 1 2 Luo YH, Yang YW, Wu CF, Wang C, Li WJ, Zhang HC (July 2021). "Fatigue prevalence in men treated for prostate cancer: A systematic review and meta-analysis". World J Clin Cases. 9 (21): 5932–5942. doi: 10.12998/wjcc.v9.i21.5932 . PMC   8316927 . PMID   34368311.
  8. ↑ Wallis, Amy; Meredith, Pamela; Stanley, Mandy (April 2020). "Cancer care and occupational therapy: A scoping review". Australian Occupational Therapy Journal. 67 (2): 172–194. doi:10.1111/1440-1630.12633. ISSN   0045-0766. PMID   31957031.
  9. ↑ Jose Stephy, Diwan Sanjay Kumar. Effect of standardized exercise program on reported fatigue in patients of cancer receiving chemotherapy. Clinical Cancer Investigation Journal 3(5): 373-376
  10. ↑ Mishra, Shiraz I.; Scherer, Roberta W.; Geigle, Paula M.; Berlanstein, Debra R.; Topaloglu, Ozlem; Gotay, Carolyn C.; Snyder, Claire (2012-08-15). "Exercise interventions on health-related quality of life for cancer survivors". The Cochrane Database of Systematic Reviews. 2012 (8): CD007566. doi:10.1002/14651858.CD007566.pub2. ISSN   1469-493X. PMC   7387117 . PMID   22895961.
  11. 1 2 Cramp F, Byron-Daniel J (November 2012). "Exercise for the management of cancer-related fatigue in adults". The Cochrane Database of Systematic Reviews. 11 (11): CD006145. doi:10.1002/14651858.CD006145.pub3. PMC   8480137 . PMID   23152233.
  12. ↑ Thompson, Paul D.; Arena, Ross; Riebe, Deborah; Pescatello, Linda S. (July–August 2013). "ACSM's New Preparticipation Health Screening Recommendations from ACSM's Guidelines for Exercise Testing and Prescription". Current Sports Medicine Reports. 12 (4) (Ninth ed.): 215–217. doi:10.1249/JSR.0b013e31829a68cf. ISSN   1537-8918. PMID   23851406.
  13. ↑ Breitbart W, Alici Y (August 2010). "Psychostimulants for cancer-related fatigue". Journal of the National Comprehensive Cancer Network. 8 (8): 933–942. doi: 10.6004/jnccn.2010.0068 . PMID   20870637.
  14. ↑ Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC (April 2011). "Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis". Journal of Pain and Symptom Management. 41 (4): 761–767. doi: 10.1016/j.jpainsymman.2010.06.020 . PMID   21251796.
  15. ↑ Gong S, Sheng P, Jin H, He H, Qi E, Chen W, et al. (2014). "Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis". PLOS ONE. 9 (1): e84391. Bibcode:2014PLoSO...984391G. doi: 10.1371/journal.pone.0084391 . PMC   3885551 . PMID   24416225.
  16. ↑ Yennurajalingam S, Bruera E (2014). "Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids". Cancer Journal. 20 (5): 319–324. doi:10.1097/PPO.0000000000000069. PMID   25299141. S2CID   29351114.
  17. ↑ Minton, Ollie; Richardson, Alison; Sharpe, Michael; Hotopf, Matthew; Stone, Patrick C. (April 2011). "Psychostimulants for the Management of Cancer-Related Fatigue: A Systematic Review and Meta-Analysis". Journal of Pain and Symptom Management. 41 (4): 761–767. doi: 10.1016/j.jpainsymman.2010.06.020 . ISSN   0885-3924. PMID   21251796.
  18. ↑ Lin, Shuanglan; Chen, Yanhan; Yang, Liu; Zhou, Jianrong (May 2013). "Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients". Journal of Clinical Nursing. 22 (9–10): 1281–1290. doi:10.1111/jocn.12228. ISSN   0962-1067. PMID   23574291.
  19. ↑ Klasson, Caritha; Helde Frankling, Maria; Lundh Hagelin, Carina; Björkhem-Bergman, Linda (January 2021). "Fatigue in Cancer Patients in Palliative Care—A Review on Pharmacological Interventions". Cancers. 13 (5): 985. doi: 10.3390/cancers13050985 . ISSN   2072-6694. PMC   7956665 . PMID   33652866.
  20. ↑ Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA, Johnson BT (January 2011). "Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis". Cancer Epidemiology, Biomarkers & Prevention. 20 (1): 123–133. doi: 10.1158/1055-9965.epi-10-0988 . PMID   21051654.
  21. ↑ Kessels E, Husson O, van der Feltz-Cornelis CM (2018). "The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis". Neuropsychiatric Disease and Treatment. 14 (14): 479–494. doi: 10.2147/ndt.s150464 . PMC   5810532 . PMID   29445285.
  22. ↑ Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, et al. (July 2010). "American College of Sports Medicine roundtable on exercise guidelines for cancer survivors". Medicine and Science in Sports and Exercise. 42 (7): 1409–1426. doi: 10.1249/MSS.0b013e3181e0c112 . PMID   20559064. S2CID   43598402.
  23. ↑ Spathis A, Booth S, Grove S, Hatcher H, Kuhn I, Barclay S (March 2015). "Teenage and Young Adult Cancer-Related Fatigue Is Prevalent, Distressing, and Neglected: It Is Time to Intervene. A Systematic Literature Review and Narrative Synthesis". Journal of Adolescent and Young Adult Oncology. 4 (1): 3–17. doi:10.1089/jayao.2014.0023. PMC   4365509 . PMID   25852970.
  24. ↑ Christen S, Roser K, Mulder RL, Ilic A, Lie HC, Loonen JJ, et al. (December 2020). "Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group". Journal of Cancer Survivorship. 14 (6): 923–938. doi:10.1007/s11764-020-00904-9. PMC   7572340 . PMID   32839902.
  25. ↑ Irestorm E, Tonning Olsson I, Johansson B, Øra I (April 2020). "Cognitive fatigue in relation to depressive symptoms after treatment for childhood cancer". BMC Psychology. 8 (1): 31. doi: 10.1186/s40359-020-00398-1 . PMC   7146960 . PMID   32272971.
  26. ↑ Irestorm E, Steur LM, Kaspers GJ, Van Eijkelenburg NK, Van der Sluis IM, Dors N, et al. (December 2022). "Fatigue trajectories during pediatric ALL therapy are associated with fatigue after treatment: a national longitudinal cohort study". Supportive Care in Cancer. 31 (1): 1. doi:10.1007/s00520-022-07456-x. PMC   9747814 . PMID   36512099.
  27. ↑ Irestorm, Elin; van Gorp, Marloes; Twisk, Jos; Nijhof, Sanne; de Bont, Judith; Grootenhuis, Martha; van Litsenburg, Raphaele (2023-09-07). "Longitudinal development of fatigue after treatment for childhood cancer: a national cohort study". Acta Oncologica. 62 (10): 1309–1321. doi: 10.1080/0284186X.2023.2254477 . ISSN   0284-186X. PMID   37676687.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.